Bionor Pharma ASA (BNRPF) 0.3850 $BNRPF
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus
Global Seasonal Influenza Therapeutics Pipeline Review 2014 - Analysis of 29 Companies & 44 Companies
M2 - Wed Apr 23, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gpdvvl/seasonal) has announced the addition of the "Seasonal Influenza - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Lentigen Corporation - Celltrion, Inc. - Liquidia Technologies, Inc. - Novartis AG - Novavax, Inc. - Crucell N.V. - BioDiem Ltd - Eurocine Vaccines AB - Colby Pharmaceutical Company - Bionor Pharma ASA - FluGen, Inc. - TechnoVax, Inc. - Theraclone Sciences, Inc. - NanoBio Corporation - Protein Sciences Corporation - Vaxart, Inc. - VBI Vaccines - AIMM Therapeutics B.V. - Cilian AG - AmVac AG - TSRL, Inc. - Vaxine Pty Ltd - AltraVax Inc. - Big DNA Ltd. - PeptiVir, Inc. - Inhibikase Therapeutics, Inc. - Codagenix, Inc. - Lakewood-Amedex Inc. For more information visit http://www.researchandmarkets.com/research/gpdvvl/seasonal
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
Marketwire - Tue Feb 11, 8:28AM CST
Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135 patients of the Company's lead candidate Vacc-4x will be published in The Lancet Infectious Diseases and available online at www.thelancet.com as of today. An editorial in the same issue, "Shot in the HAART: a vaccine therapy for HIV," adds additional perspective on the value of the trial.
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Marketwire - Tue Jan 29, 7:15AM CST
Bionor Pharma ASA (OSLO: BIONOR) today announced that Anker Lundemose, MD, PhD, DMSc (Medical Microbiology), has been appointed as President and CEO of Bionor Pharma ASA from 1 March 2013. Dr. Lundemose is a Danish citizen, and replaces Steen Kroyer, who as of 1 March will take the position as Deputy Chairman of the Board of Directors.
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus
Global Seasonal Influenza Therapeutics Pipeline Review 2014 - Analysis of 29 Companies & 44 Companies
M2 - Wed Apr 23, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gpdvvl/seasonal) has announced the addition of the "Seasonal Influenza - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Lentigen Corporation - Celltrion, Inc. - Liquidia Technologies, Inc. - Novartis AG - Novavax, Inc. - Crucell N.V. - BioDiem Ltd - Eurocine Vaccines AB - Colby Pharmaceutical Company - Bionor Pharma ASA - FluGen, Inc. - TechnoVax, Inc. - Theraclone Sciences, Inc. - NanoBio Corporation - Protein Sciences Corporation - Vaxart, Inc. - VBI Vaccines - AIMM Therapeutics B.V. - Cilian AG - AmVac AG - TSRL, Inc. - Vaxine Pty Ltd - AltraVax Inc. - Big DNA Ltd. - PeptiVir, Inc. - Inhibikase Therapeutics, Inc. - Codagenix, Inc. - Lakewood-Amedex Inc. For more information visit http://www.researchandmarkets.com/research/gpdvvl/seasonal
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
Marketwire - Tue Feb 11, 8:28AM CST
Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135 patients of the Company's lead candidate Vacc-4x will be published in The Lancet Infectious Diseases and available online at www.thelancet.com as of today. An editorial in the same issue, "Shot in the HAART: a vaccine therapy for HIV," adds additional perspective on the value of the trial.
Bionor Pharma Appoints Anker Lundemose as President and Chief Executive Officer
Marketwire - Tue Jan 29, 7:15AM CST
Bionor Pharma ASA (OSLO: BIONOR) today announced that Anker Lundemose, MD, PhD, DMSc (Medical Microbiology), has been appointed as President and CEO of Bionor Pharma ASA from 1 March 2013. Dr. Lundemose is a Danish citizen, and replaces Steen Kroyer, who as of 1 March will take the position as Deputy Chairman of the Board of Directors.
